# Valeritas

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valeritas

- Industry: Medical Devices & Equipment
- Headquarters: Bridgewater, US
- Website: www.valeritas.com
- Total disclosed funding: $238M
- Latest round: Series C (Nov 16, 2012)
- Investors on record: 11

## About

Valeritas, Inc. specializes in the development of innovative insulin delivery systems aimed at enhancing diabetes management for patients and healthcare providers alike.Valeritas, Inc. is focused on creating solutions for diabetes management, with its headquarters located in Bridgewater, US. Founded in 2006, the company has undergone significant changes, notably completing an Alternative Public Offering via a reverse merger in May 2016. In March 2017, Valeritas raised USD 52.5 mn in an IPO, selling 5.25 million shares at USD 10 per share, amounting to the total capital raised of USD 52.5 mn. The company has completed a total of 9 deals over its operational history.Valeritas offers core products that cater to diabetes management needs, including innovative insulin delivery solutions designed for patients with diabetes. These products aim to improve the quality of life for diabetes patients by providing more efficient insulin administration methods. Their services are primarily directed at healthcare providers and patients in the US, with a focus on addressing the challenges faced by individuals managing diabetes.Valeritas operates on a revenue model that revolves around the sales of its insulin delivery devices and related services. The company targets healthcare providers and patients, ensuring that its pricing strategy is aligned with the needs of the market. The revenues generated are primarily driven by the sale of its insulin delivery products, forming a sustainable revenue stream as it supports ongoing diabetes management for its clients.Valeritas, Inc. aims to innovate further in the diabetes management sector by launching new insulin delivery products designed for enhanced patient engagement and ease of use. Target markets for expansion include Europe and Asia, where the company plans to introduce its offerings by the end of 2023. The proceeds from the IPO in March 2017 will be utilized to support these initiatives, focusing on product development and market entry efforts.

## Funding rounds

- Series C, Nov 16, 2012, $76M — Advanced Technology Ventures
- Series C, Sep 8, 2011, $75M — Abingworth, Advanced Technology Ventures, CHL Medical Partners, Pitango, Welsh, Carson, Anderson & Stowe, HLM Venture Partners, ONSET Ventures, MPM BioImpact, Kaiser Permanente Ventures, Agate Medical Investments
- Series B, Dec 31, 2009, $37M — Advanced Technology Ventures
- Series B, Nov 1, 2008, $51M — Abingworth, Advanced Technology Ventures, Pitango, US Venture Partners, HLM Venture Partners, ONSET Ventures, MPM BioImpact

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series B, Series C
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B, Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series B
- HLM Venture Partners (https://capitalatlas.ai/funds/hlm-venture-partners) — Series B, Series C
- ONSET Ventures (https://capitalatlas.ai/funds/onset-ventures) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- CHL Medical Partners (https://capitalatlas.ai/funds/chl-medical-partners) — Series C
- Welsh, Carson, Anderson & Stowe (https://capitalatlas.ai/funds/welsh-carson-anderson-stowe) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C
- Agate Medical Investments (https://capitalatlas.ai/funds/agate-medical-investments) — Series C